R
Richard Szydlo
Researcher at Imperial College London
Publications - 58
Citations - 6870
Richard Szydlo is an academic researcher from Imperial College London. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 29, co-authored 45 publications receiving 6552 citations. Previous affiliations of Richard Szydlo include Medical College of Wisconsin & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin,Alexandra Bazeos,François Xavier Mahon,Lina Eliasson,Dragana Milojkovic,Marco Bua,Jane F. Apperley,Richard Szydlo,Ritti Desai,Kasia Kozlowski,Christos Paliompeis,Victoria Latham,Letizia Foroni,Mathieu Molimard,Alistair Reid,Katy Rezvani,Hugues de Lavallade,Cristina Guallar,John M. Goldman,Jamshid S. Khorashad +19 more
TL;DR: In patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses.
Journal ArticleDOI
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
Hugues de Lavallade,Jane F. Apperley,Jamshid S. Khorashad,Dragana Milojkovic,Alistair Reid,Marco Bua,Richard Szydlo,Eduardo Olavarria,Jaspal Kaeda,John M. Goldman,David Marin +10 more
TL;DR: Imatinib is highly effective in most patients with CML-CP; patients who respond are likely to live substantially longer than those treated with earlier therapies, however, approximately one third of patients still need better therapy.
Journal ArticleDOI
Results of Allogeneic Bone Marrow Transplants for Leukemia Using Donors Other Than HLA-Identical Siblings
Richard Szydlo,John M. Goldman,John P. Klein,Robert Peter Gale,Robert C. Ash,F. H. Bach,B.A. Bradley,James T. Casper,Neal Flomenberg,James Gajewski,Eliane Gluckman,P J Henslee-Downey,J M Hows,N Jacobsen,HJ Kolb,B. Lowenberg,Tohru Masaoka,Philip A. Rowlings,Paul M. Sondel,D. W. van Bekkum,J.J. van Rood,Marcus R. Vowels,Mei-Jie Zhang,Mary M. Horowitz +23 more
TL;DR: In early leukemia, alternative donor transplants have a more than twofold increased risk of treatment failure compared with HLA-identical sibling transplants, but this difference is less in advanced leukemia.
Journal ArticleDOI
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin,Amr R. Ibrahim,Claire M. Lucas,Gareth Gerrard,Lihui Wang,Richard Szydlo,Richard E. Clark,Jane F. Apperley,Dragana Milojkovic,Marco Bua,Jiri Pavlu,Christos Paliompeis,Alistair Reid,Katayoun Rezvani,John M. Goldman,Letizia Foroni +15 more
TL;DR: A single measurement of BCR-ABL1 transcripts performed at 3 months is the best way to identify patients destined to fare poorly, thereby allowing early clinical intervention.
Journal ArticleDOI
Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC
Tom Vulliamy,Anna Marrone,Richard Szydlo,Amanda J. Walne,Philip J. Mason,Philip J. Mason,Inderjeet Dokal +6 more
TL;DR: Disease anticipation is observed in families with the bone marrow failure syndrome autosomal dominant dyskeratosis congenita and this is associated with progressive telomere shortening.